After this afternoon's 1.5% surge to $284.5 per share, Alnylam Pharmaceuticals might just keep moving past its target price of $286.15. With an average analyst rating of buy, and target prices from $160.5 to $400.0, the stock's next move is anyone's guess.
Alnylam Pharmaceuticals's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.0%. The stock's short ratio is 5.06. The company's insiders own 0.42% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 95.5%. In conclusion, we believe there is mixed market sentiment regarding Alnylam Pharmaceuticals.
Institutions Invested in Alnylam Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-06-30 | Capital World Investors | 12% | 14,971,343 | $4,259,422,013 |
| 2024-06-30 | Vanguard Group Inc | 10% | 12,507,778 | $3,558,525,440 |
| 2024-06-30 | FMR, LLC | 9% | 12,164,038 | $3,460,729,690 |
| 2024-06-30 | Blackrock Inc. | 7% | 9,547,663 | $2,716,357,908 |
| 2024-06-30 | Wellington Management Group, LLP | 5% | 6,210,479 | $1,766,912,358 |
| 2024-06-30 | Baillie Gifford and Company | 5% | 6,032,656 | $1,716,320,824 |
| 2024-06-30 | Capital International Investors | 3% | 3,891,059 | $1,107,025,759 |
| 2024-06-30 | Dodge & Cox Inc | 3% | 3,780,185 | $1,075,481,551 |
| 2024-06-30 | State Street Corporation | 3% | 3,534,836 | $1,005,678,533 |
| 2024-06-30 | Price (T.Rowe) Associates Inc | 3% | 3,488,003 | $992,354,310 |
